ASX:CSLBiotechs
Does CSL (ASX:CSL) Losing TAVNEOS Authorisation Undermine Its Diversification And Regulatory Resilience Story?
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended revoking CSL Vifor’s TAVNEOS marketing authorisation in the EU, after finding manipulated and unreliable pivotal trial data and prompting CSL to halt new patient starts across EMA jurisdictions.
This setback not only raises the prospect of an impairment charge for TAVNEOS intellectual property, but also highlights how regulatory scrutiny can directly test CSL’s diversification benefits and risk...